Published in Mol Ther on December 01, 2003
Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One (2009) 1.46
Optimization of cutaneous electrically mediated plasmid DNA delivery using novel electrode. Gene Ther (2006) 1.17
Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array. Hum Gene Ther (2010) 1.02
Evaluation of delivery conditions for cutaneous plasmid electrotransfer using a multielectrode array. Gene Ther (2010) 0.86
Comparison of electrically mediated and liposome-complexed plasmid DNA delivery to the skin. Genet Vaccines Ther (2008) 0.85
A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines. Genet Vaccines Ther (2012) 0.84
Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus. Hum Vaccin Immunother (2012) 0.82
Contactless magneto-permeabilization for intracellular plasmid DNA delivery in-vivo. Hum Vaccin Immunother (2012) 0.80
Cutaneous immunization: an evolving paradigm in influenza vaccines. Expert Opin Drug Deliv (2014) 0.77
Investigation of ac-magnetic field stimulated nanoelectroporation of magneto-electric nano-drug-carrier inside CNS cells. Sci Rep (2017) 0.75
Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA (2010) 4.21
Genome-wide expression analyses of Campylobacter jejuni NCTC11168 reveals coordinate regulation of motility and virulence by flhA. J Biol Chem (2004) 1.87
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine (2004) 1.74
Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med (2005) 1.55
Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine (2002) 1.34
Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol (2005) 1.27
Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv (2011) 1.25
Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther (2002) 1.21
Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine (2005) 1.19
Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol (2004) 1.16
Genomic and protein structural maps of adaptive evolution of human influenza A virus to increased virulence in the mouse. PLoS One (2011) 1.13
Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults. Mol Ther (2009) 1.05
Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol (2005) 1.04
TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology (2004) 1.04
A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther (2007) 1.03
Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine (2007) 1.00
A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res Hum Retroviruses (2008) 0.95
Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model. J Med Virol (2004) 0.93
Seroprevalence of porcine circovirus type 2 in swine populations in Canada and Costa Rica. Can J Vet Res (2002) 0.89
Topical non-invasive gene delivery using gemini nanoparticles in interferon-gamma-deficient mice. Eur J Pharm Biopharm (2007) 0.89
In vivo cutaneous interferon-gamma gene delivery using novel dicationic (gemini) surfactant-plasmid complexes. J Gene Med (2005) 0.88
Advancing nonviral gene delivery: lipid- and surfactant-based nanoparticle design strategies. Nanomedicine (Lond) (2010) 0.87
Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix). J Pharm Pharmacol (2002) 0.86
Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen. Vaccine (2009) 0.86
Genomics-based molecular epidemiology of Campylobacter jejuni isolates from feedlot cattle and from people in Alberta, Canada. J Clin Microbiol (2008) 0.85
The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries. BMC Public Health (2011) 0.85
Thermodynamic and aggregation properties of aza- and imino-substituted gemini surfactants designed for gene delivery. Phys Chem Chem Phys (2006) 0.85
Association of polymorphisms of toll-like receptor 4 with a reduced prevalence of hay fever and atopy. Ann Allergy Asthma Immunol (2008) 0.84
A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines. Genet Vaccines Ther (2012) 0.84
Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol. Methods Mol Biol (2008) 0.84
Gemini surfactants: a new family of building blocks for non-viral gene delivery systems. Curr Gene Ther (2008) 0.83
Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect Immun (2003) 0.83
Enhanced gene expression in epithelial cells transfected with amino acid-substituted gemini nanoparticles. Eur J Pharm Biopharm (2010) 0.82
Amino acid-substituted gemini surfactant-based nanoparticles as safe and versatile gene delivery agents. Curr Drug Deliv (2011) 0.82
Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther (2002) 0.82
Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J Biotechnol (2003) 0.82
Structural and transfection properties of amine-substituted gemini surfactant-based nanoparticles. J Gene Med (2007) 0.82
Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques. Virology (2007) 0.82
Stress significantly increases mortality following a secondary bacterial respiratory infection. Vet Res (2012) 0.81
Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits. J Ocul Pharmacol Ther (2008) 0.81
Preclinical safety and biodistribution of Sindbis virus measles DNA vaccines administered as a single dose or followed by live attenuated measles vaccine in a heterologous prime-boost regimen. Hum Gene Ther (2008) 0.81
Pharmaceutical characterization of solid and dispersed carbon nanotubes as nanoexcipients. Int J Nanomedicine (2012) 0.81
Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma. Nanomedicine (Lond) (2012) 0.81
The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. Immunology (2002) 0.80
Intracellular targeting of CEA results in Th1-type antibody responses following intradermal genetic vaccination by a needle-free jet injection device. ScientificWorldJournal (2007) 0.80
A novel triple adjuvant formulation promotes strong, Th1-biased immune responses and significant antigen retention at the site of injection. Vaccine (2010) 0.80
Protection of neonatal chicks against a lethal challenge of Escherichia coli using DNA containing cytosine-phosphodiester-guanine motifs. Avian Dis (2004) 0.80
Investigation of complexes formed by interaction of cationic gemini surfactants with deoxyribonucleic acid. Phys Chem Chem Phys (2007) 0.80
Protection of chickens against a lethal challenge of Escherichia coli by a vaccine containing CpG oligodeoxynucleotides as an adjuvant. Avian Dis (2007) 0.80
Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway. J Gen Virol (2010) 0.80
Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by a particulate adjuvant. Bioelectrochemistry (2004) 0.80
Microplate quantification of plant leaf superoxide dismutases. Anal Biochem (2004) 0.79
Effect of chemical permeation enhancers on stratum corneum barrier lipid organizational structure and interferon alpha permeability. Mol Pharm (2013) 0.79
Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs. AAPS J (2005) 0.79
Mucosal dendritic cell subpopulations in the small intestine of newborn calves. Dev Comp Immunol (2011) 0.79
Non-invasive immunization on the skin using DNA vaccine. Curr Drug Deliv (2006) 0.78
Biphasic lipid vesicles (Biphasix) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. Curr Drug Deliv (2004) 0.78
Protection of neonatal broiler chicks against Salmonella Typhimurium septicemia by DNA containing CpG motifs. Avian Dis (2008) 0.78
Novel vaccine strategies. Adv Virus Res (2002) 0.77
New technology and clinical applications of nanomedicine: highlights of the second annual meeting of the American Academy of Nanomedicine (Part I). Nanomedicine (2006) 0.77
Synthesis, characterization, and use of asymmetric pyrenyl-gemini surfactants as emissive components in DNA-lipoplex systems. Langmuir (2007) 0.77
In vivo human MCP-1 transfection in porcine arteries by intravascular electroporation. Pharm Res (2005) 0.76
Drug delivery through the skin: molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.76
Accelerated immune response to DNA vaccines. DNA Cell Biol (2003) 0.76
Protection of Neonatal Broiler Chickens Following in ovo Delivery of Oligodeoxynucleotides Containing CpG Motifs (CpG-ODN) Formulated with Carbon Nanotubes or Liposomes. Avian Dis (2015) 0.76
Enhancement of immunoprotective effect of CpG-ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens. Curr Drug Deliv (2009) 0.76
In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application. Eur J Pharm Biopharm (2013) 0.75
Characteristics of respiratory viral infections during influenza season in Canadian Hutterite Communities. Influenza Other Respir Viruses (2012) 0.75
Synthesis and solution properties of gemini surfactants containing oleyl chains. Phys Chem Chem Phys (2005) 0.75
Biophysical characterization of a model antibody drug conjugate. Drug Discov Ther (2016) 0.75
Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration. Pharmacotherapy (2006) 0.75
Studies on the use of needle-free injection device on proteins. J Chromatogr A (2005) 0.75
Nanotechnology enables superior medical therapies. Curr Drug Deliv (2011) 0.75
Biphasic lipid vesicles as a subcutaneous delivery system for protein antigens and CpG oligonucleotides. Curr Drug Deliv (2006) 0.75
The 4th Annual Meeting of the American Society for Nanomedicine. J Neuroimmune Pharmacol (2014) 0.75
Evidence for lymphatic transport of insulin by topically applied biphasic vesicles. J Pharm Pharmacol (2003) 0.75